Showing 1311-1320 of 3038 results for "".
- Lindus Health and Thirty Madison Complete Enrollment of Personalized Dermatology Care Pilot Studyhttps://practicaldermatology.com/news/lindus-health-and-thirty-madison-complete-enrollment-of-personalized-dermatology-care-pilot-study/2462182/Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialized healthcare brands, announced the completion of enrolment of a pilot study to assess the effectiveness of their personalized dermatology telemedicine platform Facet. The novel teleh
- Dr. Mario E. Lacouture Named New Chief of Dermatology at NYU Langone Hospital--Long Islandhttps://practicaldermatology.com/news/dr-mario-e-lacouture-named-new-chief-of-dermatology-at-nyu-langone-hospital-long-island/2462164/Mario E. Lacouture, MD, has been named the new Chief of the Dermatology Division, Department of Medicine of NYU Langone Hospital--Long Island. Dr. Lacouture will receive an academic appointment as Professor of Medicine at NYU Grossman School of Medicine, and will serve as the Medic
- Derm-Biome Pharmaceuticals, Massachusetts General Hospital Partner for Skin Cancer Study of New Topical Rxhttps://practicaldermatology.com/news/derm-biome-pharmaceuticals-massachusetts-general-hospital-partner-for-skin-cancer-study-of-new-topical-rx/2462157/Derm-Biome Pharmaceuticals Inc. is collaborating with Massachusetts General Hospital for a study looking at Derm-Biome’s second-generation topical treatment for precancerous skin conditions and non-melanoma skin cancers. The topical is highly sel
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At
- Melanoma and Lung Cancer Drug May Also Treat Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/melanoma-and-lung-cancer-drug-may-also-treat-cutaneous-squamous-cell-carcinoma/2462149/Plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma, new research suggests. Researchers out of the University of Turku, Finland, discovered that plixorafenib (also called PLX8394) simultaneously inh
- Take That, Melanoma! ATM Kinase Inhibitors May Stop Metastasishttps://practicaldermatology.com/news/take-that-melanona-atm-kinase-inhibitors-may-stop-metastasis/2462146/Ataxia telangiectasia mutated (ATM) kinase inhibition may target the metastatic capacity of melanoma cells, according to a research team led by Wolfgang Weninger and Shweta Tikoo from MedUni Vienna's Department of Dermatology. The results of the study, which appe
- AD Pipeline Watch: Rademikibart Maintains Efficacy Out to Week 52https://practicaldermatology.com/news/ad-pipeline-watch-rademikibart-maintains-efficacy-out-to-week-52/2462145/Connect Biopharma’s rademikibart continues to wow in patients with moderate-to-severe atopic dermatitis, according to topline results from the Stage 2 (maintenance period) of its China pivotal trial. Rademikibart is an inhibitory human monoclonal antibody against the IL-4Rα
- Super Melanin May Heal Skin Injuries From Sunburn, Chemical Burnshttps://practicaldermatology.com/news/super-melanin-may-heal-skin-injuries-from-sunburn-chemical-burns/2462125/A synthetic, biomimetic melanin may heal the damage that occurs when your skin is exposed to sunlight or environmental toxins. In a new study, Northwestern University scientists show that their synthetic melanin, mimicking the natural melanin in human skin, can be applied
- ‘Bliss’ Compound May Hold Out Hope for Autoimmune Skin Diseasehttps://practicaldermatology.com/news/bliss-compound-may-hold-out-hope-for-autoimmune-skin-disease/2462112/A marijuana-like compound holds out promise as a new treatment for a severe autoimmune skin disease called skin lupus, suggests a recent study out of George Washington University. If the results of the mouse study can be replicated in human trials, the compound, known as anandamide
- ESMO News: Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%https://practicaldermatology.com/news/esmo-news-major-pathologic-response-to-neoadjuvant-pembrolizumab-in-advanced-melanoma-trial-exceeds-50/2462089/In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other re